Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Digestion ; 88(4): 252-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24335273

RESUMO

BACKGROUND/AIMS: This prospective study investigated the performance of pre-endoscopy and the complete Rockall scores in predicting the occurrence of adverse outcomes and the need for endoscopic or surgical intervention in patients with nonvariceal upper gastrointestinal bleeding. METHODS: All 656 consecutive patients who underwent endoscopy due to nonvariceal upper gastrointestinal bleeding between 2007 and 2011 were included. Receiver operating characteristic (ROC) curves were plotted for the outcomes of therapeutic intervention, rebleeding and death. The discriminative accuracy of the risk scores was assessed by the area under the ROC curve. RESULTS: Endoscopic treatment was performed in 55.2% of the patients. Rebleeding and mortality rates were 7.6 and 3.8%, respectively. The pre-endoscopy Rockall scores showed unsatisfactory accuracy in predicting the need for intervention, rebleeding or death, as shown by the respective area under the ROC curve values of 0.52, 0.52 and 0.65. The accuracy of the complete Rockall score in predicting rebleeding was poor (area under ROC: 0.52), but it was higher for mortality (area under ROC: 0.69). CONCLUSIONS: The pre-endoscopy Rockall score was not useful for predicting the need for therapeutic intervention or adverse outcomes. The complete Rockall score showed an acceptable performance in predicting mortality, but was unable to predict rebleeding.


Assuntos
Hemorragia Gastrointestinal/terapia , Neoplasias Gastrointestinais/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Área Sob a Curva , Brasil , Feminino , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/mortalidade , Hemostase Endoscópica , Humanos , Masculino , Síndrome de Mallory-Weiss/complicações , Pessoa de Meia-Idade , Avaliação das Necessidades , Úlcera Péptica Hemorrágica/mortalidade , Úlcera Péptica Hemorrágica/terapia , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROC , Recidiva , Fatores de Tempo
2.
Clin Chem Lab Med ; 48(12): 1809-12, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20961199

RESUMO

BACKGROUND: Helicobacter pylori (H. pylori) infection has been associated with iron deficiency anemia. However, results reported in the literature are contradictory. The goal of the present study was to study the possible association between H. pylori infection and iron deficiency in a sample of adults. METHODS: One hundred and fifty individuals were studied (H. pylori-positive n=75; H. pylori-negative n=50). The presence of anemia was determined using red cell indices and reticulocyte hemoglobin content (CHr). Iron status was assessed based on serum iron and ferritin levels. Possible involvement of inflammatory activity in erythropoiesis was investigated by measuring the correlation between C-reactive protein (CRP) and red cell indices and iron status. RESULTS: There were no significant differences in the hematological or biochemical parameters for the two groups. Iron deficiency was diagnosed in six individuals, but no difference in prevalence was found between the H. pylori-positive and H. pylori-negative groups. A weak but significant inverse correlation was observed between CRP and CHr concentrations and between serum gastrin and CHr in the H. pylori-positive group. These results suggest a reduction in iron availability for reticulocyte hemoglobinization, but insufficient to cause anemia. CONCLUSIONS: H. pylori infection was not a determining factor for development of iron deficiency in our study population.


Assuntos
Anemia Ferropriva/etiologia , Gastrite/complicações , Infecções por Helicobacter/complicações , Brasil , Proteína C-Reativa/análise , Índices de Eritrócitos , Eritropoese , Feminino , Humanos , Inflamação , Ferro/metabolismo , Masculino
3.
World J Gastroenterol ; 11(23): 3566-9, 2005 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-15962376

RESUMO

AIM: To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer. METHODS: One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d. or (2) 2-wk regimen of the same treatment. Eradication of the infection was considered when both the histologic examination and the urease test were negative for the infection 3 mo after treatment. RESULTS: By intention to treat analysis, Helicobacter pylori (H pylori) was eradicated in 73% and 76% of patients, respectively treated for 1 or 2 wk (P>0.05). By per protocol analysis, the eradication rates were 80% and 83%, respectively, in patients treated for 1 or 2 wk (P>0.05). Nine patients (8.2%) reported minor side effects. CONCLUSION: One-week therapy with ranitidine bismuth citrate and clarithromycin is safe, well tolerated and effective for treatment of H pylori infection, and appears to be comparable to the 2-wk regimen in terms of efficacy.


Assuntos
Antiulcerosos/uso terapêutico , Bismuto/uso terapêutico , Claritromicina/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Úlcera Péptica/tratamento farmacológico , Ranitidina/análogos & derivados , Adulto , Idoso , Antibacterianos/uso terapêutico , Brasil , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Úlcera Péptica/microbiologia , Ranitidina/uso terapêutico , Resultado do Tratamento
4.
Gastroenterol Res Pract ; 2013: 384561, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24319453

RESUMO

Background. Fecal immunochemical tests (FITs) have been used for colorectal cancer (CRC) screening in several countries. There is lack of information concerning diagnostic performances of this method in Brazil. Methods. Patients scheduled for elective colonoscopy provided one stool sample one week before colonoscopy. The accuracy of a qualitative FIT for detection of CRC and advanced adenomas was determined. Results. Overall 302 patients completed the study. Among them, 53.5% were high risk patients referred for screening or surveillance. Nine (3%) CRCs and 11 (3.6%) advanced adenomas were detected by colonoscopy. Sensitivity and specificity for CRC were, respectively, 88.9% and 87.6%. For advanced adenomas, sensitivity was 63.6% and specificity 87.6%. Conclusion. Our results showed good sensitivity and specificity of the FIT for detecting advanced neoplasias. This method may be a valuable tool for future screening programs in Brazil.

5.
J Crit Care ; 24(4): 627.e7-13, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19931156

RESUMO

PURPOSE: The study aimed to evaluate whether ranitidine and pantoprazole are able to maintain gastric pH >or=4 in septic patients. MATERIALS AND METHODS: Twenty intensive care unit patients from a university teaching hospital with sepsis were included in this study. Ten patients received ranitidine (50 mg as an intermittent bolus 3 times a day) and 10 received pantoprazole (40 mg as an intermittent bolus twice a day). Gastric pH was measured continuously for 48 hours. Endoscopy of the upper digestive tract, gastric biopsy, and investigation for Helicobacter pylori were carried out before and at the end of the study. RESULTS: pH values >or=4 were maintained for 46.27% +/- 38.21% and 81.57% +/- 19.65% of study time in the ranitidine and pantoprazole groups, respectively (P = .04). CONCLUSIONS: Intravenous ranitidine was unable to maintain gastric pH above 4 in septic patients. All cases in the ranitidine group in whom pH remained above 4 had gastric hypotrophy or atrophy. Pantoprazole successfully maintained pH levels above 4.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Antiulcerosos/uso terapêutico , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Ranitidina/uso terapêutico , Sepse/tratamento farmacológico , APACHE , Adulto , Feminino , Ácido Gástrico/química , Humanos , Concentração de Íons de Hidrogênio , Masculino , Pessoa de Meia-Idade , Pantoprazol , Fatores de Tempo
8.
Arq. bras. med ; 65(3): 311-7, maio-jun. 1991. tab
Artigo em Português | LILACS | ID: lil-137747

RESUMO

Foram estudados 40 pacientes com úlcera péptica duodenal distribuídos randomicamente em dois grupos de vinte. Um grupo recebeu antiácido líquido de alta potência (7,06mEq/ml) por quatro semanas e outro grupo recebeu cimetidina por igual período. Todos os pacientes foram avaliados clinicamente no pré-tratamento e duas a quatro semanas após, com exames endoscópicos realizados na admissäo e após quatro semanas. A eficácia, considerada como cicatrizaçäo da úlcera duodenal, foi equivalente para ambos os tratamentos näo havendo diferença significante. É discutida a importância da capacidade de neutralizaçäo ácida no tratamento da úlcera duodenal


Assuntos
Humanos , Adolescente , Adulto , Pessoa de Meia-Idade , Antiácidos , Cimetidina/uso terapêutico , Úlcera Duodenal/tratamento farmacológico , Cimetidina/efeitos adversos , Úlcera Duodenal/diagnóstico
9.
GED gastroenterol. endosc. dig ; GED gastroenterol. endosc. dig;21(2): 59-63, mar.-abr. 2002.
Artigo em Português | LILACS | ID: lil-316477

RESUMO

A escleroterapia endoscópica é um método terapêutico muito difundido e utilizado no tratamento das varizes esofágicas. É um procedimento de baixo custo, factível de ser realizado na maioria dos serviços de endoscopia, contribuindo para diminuir o risco de hemorragia nos hepatopatas crônicos. Foram analisados tardiamente 95 doentes hepatopatas (47 cirróticos, 42 esquistossomóticos e seis outras hepatopatias) no Gastrocentro-Unicamp, sendo 65 classificados com o child A (68,4por cento), 25 com child B(26,3por cento) e cinco com child C (5,2por cento), submetidos a escleroterapia de varizes, seguidos por tempo variável entre dois e 11 anos (média de três anos e quatro meses). O agente esclerosante mais utilizado foi o oleato de etanolamina a 5por cento em 66 casos(69,5por cento) e o alcool absoluto em 29 casos (30,5por cento). A escleroterapia foi paravasal, com o número médio de nove sessões por doente. O ressangramento na vigência da escleroterapia ocorreu em 47 doentes (49,5por cento), não havendo diferença significativa (p>0,05) entre os agentes esclerosantes utilizados. A mortalidade durante o tratamento foi de 12,6por cento. Os doentes incluídos no grupo A de Child tiveram sobrevida maior e estatisticamente significante ( p < 0,05) quando comparados com os dos grupos B e C. Considerando as etiologias das hepatopatias não houve diferença estatistica (p >0,05) na sobrevida de portadores de esquistossomose, quando comparada com as demais hepatopatias. Quarenta e seis doentes (48,5por cento) tiveram sobrevida maior que 60 meses. Concluindo, a escleroterapia endoscópica continua sendo um recurso terapêutico muito útil nos dias atuais. A longo prazo, a indicação de endoscopias digestivas periodicas e sessões de escleroterapia em hepatopatas contribuem para elevar a sobbrevida


Assuntos
Humanos , Masculino , Feminino , Adulto , Endoscopia , Hepatopatias , Escleroterapia , Varizes Esofágicas e Gástricas/terapia , Estudos Retrospectivos , Esquistossomose
10.
GED gastroenterol. endosc. dig ; GED gastroenterol. endosc. dig;13(2): 76-8, abr.-jun. 1994. ilus, tab
Artigo em Português | LILACS | ID: lil-172281

RESUMO

A polipose de glândulas fúndicas é uma manifestaçao comum na polipose familiar e rara na populaçao geral. Os autores descrevem quatro casos de PGF em pacientes sem polipose familiar, com revisao da literatura, discutindo a incidência, sintomatologia, diagnóstico, risco de malignizaçao e conduta nos pacientes com esta doença.


Assuntos
Humanos , Feminino , Adulto , Neoplasias Gástricas/diagnóstico , Pólipos do Colo/diagnóstico , Pólipos Intestinais/diagnóstico , Gastroscopia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA